SCHEMBL22314946

SCHEMBL22314946

FC(F)(F)Oc1ccc(-c2ccc(OCc3ccccc3)cn2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.50
SCN10A Q9Y5Y9 2/20 0.49
MRGPRX4 Q96LA9 2/20 0.47
MEN1 O00255 1/20 0.47
NPC1 O15118 1/20 0.47
POLB P06746 1/20 0.47
RAB9A P51151 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
P4HTM Q9NXG6 1/20 0.47
CHRM5 P08912 1/20 0.46
ENPP3 O14638 1/20 0.44
ENPP1 P22413 1/20 0.44
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5105144 0.84 MRGPRX4 (0.58) SCN10AMRGPRX4RAB9ASMN1; SMN2CYP2C19
SCHEMBL9048918 0.82 CYP1A2 (0.64) DGAT1MEN1NPC1POLBRAB9A
SCHEMBL5784957 0.82 MRGPRX4 (0.63) MRGPRX4RAB9ASMN1; SMN2CYP2C19GAA
SCHEMBL1765500 0.81 DGAT1 (0.53) DGAT1MRGPRX4MEN1NPC1POLB
SCHEMBL22315060 0.80 SCN10A (0.47) SCN10AMRGPRX4MEN1NPC1POLB
SCHEMBL22314933 0.79 ADORA2A (0.46) SCN10AMRGPRX4MEN1NPC1POLB
SCHEMBL11310984 0.77 MRGPRX4 (0.58) MRGPRX4RAB9ASMN1; SMN2CYP2C19GAA
SCHEMBL4380372 0.77 MRGPRX4 (0.57) MRGPRX4RAB9ASMN1; SMN2CYP2C19GAA
SCHEMBL21034957 0.77 KDM1A (0.47) NPC1RAB9ASMN1; SMN2CHRM5CYP3A4
SCHEMBL31374887 0.77 CHRM5 (0.44) SCN10ANPC1RAB9ACHRM5CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219938-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PREC MEDICINES INC (US) 2023-07-13 US disclosed
US-20230219938-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PREC MEDICINES INC (US) 2023-07-13 US disclosed
US-20200247793-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2020-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247793-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B DGAT1 458/4885SCN10A 24/4885MRGPRX4 2879/4885
US-20230219938-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B DGAT1 458/4885SCN10A 24/4885MRGPRX4 2879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.